Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?
| Autor: | Le Maux, Amélie Huynh1,2 a.lemaux@pelvipharm.com, Pignol, Bernadette3 bernadette.pignol@ipsen.com, Behr-Roussel, Delphine1,2 d.behr.roussel@pelvipharm.com, Blachon, Jean-Luc3 jean-luc.blachon@ipsen.com, Chabrier, Pierre-Etienne3 pierre-et.chabrier@ipsen.com, Compagnie, Sandrine1,2 s.compagnie@pelvipharm.com, Picaut, Philippe3 philippe.picaut@ipsen.com, Bernabé, Jacques1,2 j.bernabe@pelvipharm.com, Giuliano, François2,4 francois.giuliano@uvsq.fr, Denys, Pierre2,4 pierre.denys@rpc.aphp.fr |
|---|---|
| Zdroj: | Toxins. Dec2015, Vol. 7 Issue 12, p5462-5471. 10p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|